ArticleBMC infectious diseases2025
Epidemiology and economic burden of hospitalizations attributable to Respiratory Syncytial Virus (RSV) infection among infants in France, 2016 to 2023 - EPIBREATHE study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMost of the clinical and economic burden of Respiratory Syncytial Virus (RSV) in pediatric populations is concentrated among infants aged < 1 year. This study aimed to estimate the recent incidence, healthcare costs and rehospitalization risk associated with RSV-related hospitalizations in infants < 1 year of age in France.
methodsThe study analyzed the French National Hospital Database (PMSI) between January 1, 2016 and December 31, 2023. Outside of the classically defined epidemic season (October–March), RSV-related hospitalizations in infants were identified based on RSV-specific diagnosis codes and by both specific and non-specific RSV diagnosis codes during the epidemic season. Analyses were stratified by calendar months, by age in months and weeks for infants under 2 months. Lengths of stays (LOS), intensive care units (ICU) admissions, costs and rehospitalization rates were described. Rehospitalization rate was assessed using the Kaplan-Meier estimator.
resultsA total of 354,837 RSV-related hospitalizations were identified, representing an average of 44,355 per year, and a rate of 4.9 hospitalizations per 1,000 births. Overall, 76.4% occurred between November and February (epidemic peak), and 21.1% in September-October and March-April (transition months). ICU admission was observed in 27.2% of hospitalizations. The median (Q1–Q3) hospital and ICU LOS were 3.0 days (1.0–5.0) and 3.0 days (2.0–5.0), respectively. The mean (SD) hospital cost was €3,110 (€4,694), for an annual cumulative cost of €137.9 million. Younger infants had longer and costlier stays, with greater need for ICU. Infants younger than 3 months accounted for 46.5% of the hospitalizations, 58.5% of ICU stays and 54.9% of cumulative LOS. RSV-associated rehospitalization rates [95%CI] were 10.1% [10.0%–10.3%] and 11.7% [11.5%–11.9%] at three and 12 months, respectively.
conclusionsRSV infections are estimated to cause > 44,000 hospitalizations annually in infants in France, representing a total cost exceeding €130 million, annually. This study highlighted the impact of transitional months in RSV circulation. It also emphasized that the youngest patients (< 3 months) represent nearly 50% of the economic burden. To reduce RSV disease burden, it is essential to protect infants against RSV both inside and outside the classically defined epidemic season, especially in the first months of life. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.